UNSPSC 51352429: Estrogens/methyltestosterone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS900. This VA Drug Class (HS900) classifies this compound as belonging to the group HORMONES/SYNTHETICS/MODIFIERS, OTHER.

UNSPSC 51352429 Estrogens/methyltestosterone is a Commodity code under which state and local governments procure pharmaceutical products—specifically estrogens and methyltestosterone formulations—as components of pharmacy benefit programs, Medicaid formularies, and employee health plans serving public sector populations. Recent solicitations show state health agencies and cooperative purchasing alliances sourcing these products through direct-to-manufacturer channels, generic multi-source procurement frameworks, and established wholesaler networks to manage costs and ensure consistent supply to state facilities and beneficiaries. Issuing bodies include state health and human services departments (notably the Texas Health and Human Services Commission and the Minnesota Department of Administration) and multistate cooperative purchasing consortia such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which aggregates demand across multiple state and local participants to negotiate volume pricing and favorable terms.

Recent activity centers in Texas and Minnesota. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs that could bypass traditional pharmacy benefit managers and wholesalers, signaling the state's interest in alternative procurement and cost-management models for pharmaceutical distribution. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 with a March 26, 2026, response deadline to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products across participating state and local facilities, including Oregon; the RFP requires vendor compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintenance of relationships with authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC), and payment of a 3 percent administrative fee, with contract effectiveness set for July 1, 2026. Evaluation under the MMCAP RFP weights price competitiveness at 75 percent, with remaining criteria addressing fixed pricing, administrative compliance, EDI capability, and administrative fee agreement.